Can Colgate-Palmolive's (CL) Strategy Navigate Cost Pressures and Slower Organic Growth Expectations?

• In the past week, Colgate-Palmolive reported third-quarter results with steady sales at US$5.13 billion and updated earnings guidance, indicating organic sales growth of 1–2% for 2025, below earlier expectations.
• This guidance revision accompanied management’s comments on persistent cost pressures and consumer uncertainty, providing insight into operational headwinds facing the business.
• We'll examine how Colgate-Palmolive's lowered organic sales outlook and management commentary on cost inflation affect its forward-looking investment narrative.

Outshine the giants: these 25 early-stage AI stocks could fund your retirement.

Colgate-Palmolive Investment Narrative Recap

To be a shareholder in Colgate-Palmolive, one must believe in the long-term durability of its global brands and the steady demand for daily-use household products. The recent downward revision of organic sales growth guidance to 1–2% for 2025 underscores the near-term pressure from cost inflation and consumer caution, but these updates do not materially shift the core investment catalyst: ongoing brand investment and expansion into emerging markets. The key risk that stands out is persistent cost inflation, which continues to weigh on profitability and margins in the face of evolving consumer habits.

Among the company’s recent announcements, the large share buyback program, most recently repurchasing over three million shares for US$258.6 million, aligns with management's emphasis on returning cash to shareholders even as near-term growth moderates. This capital allocation decision is particularly interesting given the backdrop of ongoing cost pressures and revised growth expectations, offering investors a contrasting signal amid mixed short-term catalysts.

In contrast, investors should not overlook the growing margin pressure from higher raw material and packaging costs, especially as...

Read the full narrative on Colgate-Palmolive (it's free!)

Colgate-Palmolive’s outlook anticipates $22.4 billion in revenue and $3.5 billion in earnings by 2028. This requires 3.8% annual revenue growth and a $0.6 billion increase in earnings from the current $2.9 billion.

Uncover how Colgate-Palmolive's forecasts yield a $88.84 fair value, a 13% upside to its current price.

Exploring Other Perspectives

The Simply Wall St Community provided 4 fair value estimates for Colgate-Palmolive, ranging from US$87 to US$122.83. With margin pressure intensifying, your view on cost risks could set your expectations apart from the crowd.

Explore 4 other fair value estimates on Colgate-Palmolive - why the stock might be worth just $87.00!

Build Your Own Colgate-Palmolive Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Colgate-Palmolive research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Colgate-Palmolive research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Colgate-Palmolive's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• We've found 16 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• Explore 28 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com